Nitrase Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $45M

  • Investors
  • 10

Nitrase Therapeutics General Information

Description

Developer of a biopharmaceutical platform designed to identify nitrases and their nitro-substrates and understand their role in disease. The company's platform is based on knowledge of protein nitration and the enzymatic activity of nitrases, enabling medical professionals to develop small-molecule drugs and antibodies targeting core biological processes in diseases such as Parkinson's disease and cancer.

Contact Information

Formerly Known As
Nitrome, Nitrome Biosciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Corporate Drive
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 1 Corporate Drive
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nitrase Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 02-Nov-2021 $45M Completed Generating Revenue
4. Accelerator/Incubator 07-Sep-2018 Completed Generating Revenue
3. Seed Round 12-Jul-2018 Completed Generating Revenue
2. Grant 01-Jan-2018 $2.5K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Nitrase Therapeutics’s complete valuation and funding history, request access »

Nitrase Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Nitrase Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nitrase Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical platform designed to identify nitrases and their nitro-substrates and understand their
Drug Discovery
South San Francisco, CA
21 As of 2025

Houston, TX
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nitrase Therapeutics Competitors (15)

One of Nitrase Therapeutics’s 15 competitors is GlycosBio, a Venture Capital-Backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlycosBio Venture Capital-Backed Houston, TX
Editas Medicine Formerly VC-backed Cambridge, MA
Voyager Therapeutics Formerly VC-backed Lexington, MA
PlantForm Venture Capital-Backed Toronto, Canada
Dynavax Technologies Formerly VC-backed Emeryville, CA
You’re viewing 5 of 15 competitors. Get the full list »

Nitrase Therapeutics Patents

Nitrase Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026124614-A1 Methods of treating disorders Pending 13-Dec-2024
AU-2025250241-A1 Ny39 alpha-synuclein antibodies and methods of use thereof Pending 02-Apr-2024
WO-2025212730-A1 Ny39 alpha-synuclein antibodies and methods of use thereof Pending 02-Apr-2024
CA-3236572-A1 Methods of diagnosing a synucleinopathy Pending 01-Nov-2021
EP-4427039-A1 Methods of diagnosing a synucleinopathy Pending 01-Nov-2021 G01N33/6896
To view Nitrase Therapeutics’s complete patent history, request access »

Nitrase Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nitrase Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
Breakthrough 307 Angel Group Minority
Bristol-Myers Squibb Corporation Minority
Angel (individual) Minority
You’re viewing 5 of 10 investors. Get the full list »

Nitrase Therapeutics FAQs

  • When was Nitrase Therapeutics founded?

    Nitrase Therapeutics was founded in 2012.

  • Where is Nitrase Therapeutics headquartered?

    Nitrase Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Nitrase Therapeutics?

    Nitrase Therapeutics has 21 total employees.

  • What industry is Nitrase Therapeutics in?

    Nitrase Therapeutics’s primary industry is Drug Discovery.

  • Is Nitrase Therapeutics a private or public company?

    Nitrase Therapeutics is a Private company.

  • What is the current valuation of Nitrase Therapeutics?

    The current valuation of Nitrase Therapeutics is .

  • What is Nitrase Therapeutics’s current revenue?

    The current revenue for Nitrase Therapeutics is .

  • How much funding has Nitrase Therapeutics raised over time?

    Nitrase Therapeutics has raised $45.9M.

  • Who are Nitrase Therapeutics’s investors?

    AbbVie Ventures, Alexandria Venture Investments, Breakthrough 307, Bristol-Myers Squibb, and are 5 of 10 investors who have invested in Nitrase Therapeutics.

  • Who are Nitrase Therapeutics’s competitors?

    GlycosBio, Editas Medicine, Voyager Therapeutics, PlantForm, and Dynavax Technologies are some of the 15 competitors of Nitrase Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process